Financial Statements

Mithra Pharmaceuticals SA (MITRA.BR)

3.11 €

-0.04 (-1.27%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) -220-128-98-86-
Net Income -117-92-27-12-35
Stock Dividends 0--41-51
Dividend Paid -----
Retained Earnings -337-220-128-98-86

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 99948460-
Annual Depreciation 2922253572
Capital Expenditure -21-16-15-10-12
Net PPE 10899948460

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -5555
New Purchases -----
Intangible and Goodwill 55555

Mithra Pharmaceuticals SA income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Mithra Pharmaceuticals SA FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.